£Ç£Ï£ÔGlutamic Oxaloacetic Transaminase¡Ê¥°¥ë¥¿¥ß¥ó»À¥ª¥¥µ¥í¿Ý»À¥È¥é¥ó¥¹¥¢¥ß¥Ê¡¼¥¼¡Ë¤Îά¡£Ê̾ÎAST¡£
¢ª
AST£Ç£Ð£ÔGlutamic Pyruvic Transaminase¡Ê¥°¥ë¥¿¥ß¥ó»À¥Ô¥ë¥Ó¥ó»Àž°Ü¹ÚÁǡˤÎά¡£Ê̾ÎALT¡£
¢ª
ALT£Ç£Ö£È£ÄGraft versus Host Disease¡Ê°Ü¿¢ÊÒÂнɼçÈ¿±þÉ¡ˤÎά¡£°Ü¿¢¤Ëȼ¤¦µñÀäÈ¿±þ¡¢ÉûºîÍѤΰì¼ï¤Ç¡¢¥É¥Ê¡¼Í³Íè¤Î¥ê¥ó¥Ñµå¤¬´µ¼Ô¤ÎÂΤò¾¿Í¤Èǧ¼±¤·¤Æ¹¶·â¤¹¤ë¸½¾Ý¡£µÞÀ¡Ê°Ü¿¢¸å100Æü°ÊÆâ¡Ë¤ÈËýÀ¡Ê°Ü¿¢¸å100Æü°Ê¹ß¡Ë¤¬¤¢¤ê¡¢¾É¾õ¤¬½Å¾É²½¤¹¤ë¤ÈÌȱÖÍÞÀ©ºÞ¤Ç¼£ÎŤ¹¤ë¡£°Ü¿¢¸å¤ËGVHD¤òȯ¾É¤·¤¿¾ì¹ç¤ÏºÆÈ¯Î¨¤¬Äã²¼¤¹¤ë¤È¤¤¤¦Åý·×¤¢¤ê¡£
£Ç£Ö£ÌGraft versus Leukemia¡Ê°Ü¿¢ÊÒÂÐÇò·ìÉ¡ˤÎά¡£Æ±¼ï°Ü¿¢¸å¤Ë¥É¥Ê¡¼¤Î¥ê¥ó¥Ñµå¤¬»Ä¸¤¹¤ëÇò·ìɺÙ˦¤ò°Ûʪ¤Èǧ¼±¤·¤Æ¹¶·â¤¹¤ëºîÍѤǡ¢ºÆÈ¯ÍÞÀ©¤ËƯ¤¯¡£
£È£Å£Ð£Á¥Õ¥£¥ë¥¿¡¼¶õµ¤Ãæ¤ÎºÙ¶Ý¤ä¿¿¶ÝÅù¤òßɲ᤹¤ëµ¡Ç½¤ò»ý¤Ä¥Õ¥£¥ë¥¿¡¼¤Ç¡¢°ìÈÌŪ¤Ë̵¶ÝÉÂÅ̵¶Ý¼¼¤ËÀßÃÖ¤µ¤ì¤Æ¤¤¤ë¤â¤Î¡£À¶¾ôÅ٤ˤè¤Ã¤Æ¥¯¥é¥¹10000¡¢¥¯¥é¥¹5000¡¢¥¯¥é¥¹100¡ÊÉס¹¤Î¿ôÃͤ¬¶õµ¤Ãæ1ΩÊý¥Õ¥£¡¼¥ÈÃæ¤Î¥Á¥ê¤Î¿ô¤ò¼¨¤¹¡Ë¤ËʬÎव¤ì¤ë¡£
£È£ç£âHemogrobin¡Ê¥Ø¥â¥°¥í¥Ó¥ó¡Ë¤Îά¡£
¢ª
¥Ø¥â¥°¥í¥Ó¥ó£È£Ì£ÁHuman Leukocyte Antigen¡Ê¥Ò¥ÈÇò·ìµå·¿¹³¸¶¡Ë¤Îά¡£Çò·ìµå¤Î·ì±Õ·¿¤È¸À¤¨¤ë¤â¤Î¤Ç¤¢¤ê¡¢°ìÈÌŪ¤Ë·ì±Õ·¿¤È¤¤¤¦¤ÈA,B,AB,O·¿¤È¤¤¤Ã¤¿ÀÖ·ìµå¤Î·¿¤ò»Ø¤¹¤¬¡¢HLA·¿¤ÏÇò·ìµå¤Î·¿¤ò¼¨¤·¤Æ¤¤¤ë¡£ÂåɽŪ¤Ê¤Î¤ÏAºÂ¡Ê28¼ï¡Ë¡¢BºÂ¡Ê60¼ï¡Ë¡¢DRºÂ¡Ê21¼ï¡Ë¤Î3ºÂ¤Ç¡¢¥Ò¥È¤ÎHLA·¿¤Ï³ÆºÂ¤«¤é2¼ï·×6ºÂ¤«¤é¹½À®¤µ¤ì¡¢¿ôËüÄ̤ê¤òͤ¨¤ëÁȹ礻¤¬Â¸ºß¤¹¤ë¤È¤µ¤ì¤ë¡£¹ü¿ñ°Ü¿¢¤Î²ÄÈݤò¸¡Æ¤¤¹¤ë¾å¤Ç¤Ï¤³¤ÎHLA6ºÂ¤Î°ìÃ×¾õ¶·¤¬ºàÎÁ¤È¤Ê¤ê¡¢°ìÈÌŪ¤Ë5ºÂ°Ê¾å¤Î°ìÃפ¬É¬ÍפȤµ¤ì¤ë¡ÊçÁÂÓ·ì°Ü¿¢¤Î¾ì¹ç¤Ï4ºÂ°Ê¾å¤Î°ìÃפ¬Ìܰ¡ˡ£¾°¡ÊAºÂ¡¢BºÂ¡¢DRºÂ¡Ë¤ÎÁȤÏξ¿Æ¤«¤é¤½¤ì¤¾¤ì°äÅÁ¤µ¤ì¤ë°Ù¡¢·ì±ï·»Äï´Ö¤Ç¤Î6ºÂ°ìÃ׳ÎΨ¤Ï25%¤Ç¤¢¤ë¡£
£É£Ö£ÈIntervenous Hyperalimentation¡ÊÃæ¿´ÀÅÌ®±ÉÍÜË¡¡Ë¤Îά¡£Ãæ¿´ÀÅÌ®¥«¥Æ¡¼¥Æ¥ë¤Î¤³¤È¤ò»Ø¤·¼¨¤¹¤³¤È¤¬Â¿¤¤¡£
¢ª
Ãæ¿´ÀÅÌ®¥«¥Æ¡¼¥Æ¥ë£Ê£Í£Ä£ÐJapan Marrow Donor Program¡ÊÆüËܹü¿ñ¥Ð¥ó¥¯¡Ë¤Îά¡£
¢ª
¹ü¿ñ¥Ð¥ó¥¯
¥Ö¥í¥°ÆÉ¤ó¤À¤é²¶¤â´èÄ¥¤é¤Í¤Ð¡¢¤È»×¤¨¤¿¡£´èÄ¥¤ë¤¾¡£totoÍɤì¤Ê¤¤¿´¤¤Ã¤È¤¤Ã¤È¿´¤¬À¸¤¤Æ¤¤¤ì¤Ð¡¢ºÙ˦¤âÀ¸¤¤Æ³è¤¤Æ¤¯¤ì¤ë¥Ï¥ºŽ¡¤À¤è¤ÍŽ¡RINÍɤì¤Ê¤¤¿´¤ªËߤǤ¹¤Í¡£µ¢¤Ã¤ÆÍè¤Æ¤ë¤Î¤Ç¤¹¤«¤Í¡©Î§µ·¤ÊÊý¤À¤«¤é³§¤Î¤È¤³²ó¤Ã¤Æ¤ë¤«¤â¤·¤ì¤Ê¤¤¤Ç¤¹¤Í¡£JIROÍɤì¤Ê¤¤¿´¤Ï¤¸¤á¤Þ¤·¤Æ¡£Î¹Î©¤¿¤ì¤Æ¤«£´¥ö·î¤¬¤¿¤È¤¦¤È¤·¤Æ¤¤¤Þ¤¹¤Í¡£²¿ÅÙ¤âÆÉ¤ßÊÖ¤·¤Æ¤ë¤È¥³¥á¥ó¥È¤¹¤ë¤ÈÊÖ»ö¤¬Ê֤äƤ¯¤ëµ¤¤¬¤·¤Æ¤·¤Þ¤¤¤Þ¤¹¡£Ê¸¾Ï¤«¤éÞú¤ß½Ð¤¿TK¤µ¤ó¤Î¿ÍʪÁü¤¬²ñ¤Ã¤¿»ö¤â¤Ê¤¤¤ÎROMÍɤì¤Ê¤¤¿´¤Þ¤¿¡¢´ó¤ê¤Þ¤·¤¿¤¢¤¤¤«¤ï¤é¤º¡¢¤¿¤¯¤µ¤ó¤ÎÊý¡¹¤¬£Ô£Ë¤µ¤ó¤Ë²ñ¤¤¤Ë¡Ê?¡ËÍè¤Æ¤ë¤ó¤Ç¤¹¤Í¡£
£Ô£Ë¤µ¤ó¡¢¤Ï¤¤¡¢º£Æü¤Îº¹¤·Æþ¤ì¥¿¡¼¥Ë¥ãÍɤì¤Ê¤¤¿´¼õ¤±¤È¤á¤ëͦµ¤º£Æü½é¤á¤Æ¤ª¼ÙË⤵¤»¤Æ¤¤¤¿¤À¤¤Þ¤·¤¿¡£Â©»Ò¤¬Â¿ç£¾É¸õ·²¡¦ç£Ç¿Ë¦¤ÇÆþ±¡¼£ÎŤò¤·¤Æ¤¤¤Þ¤¹¡£½ÅÆÆ¤Ê¿´¼À´µ¤ò¹çÊ»¤¹¤ë¤«¤â¤·¤ì¤Ê¤¤¡Ä¤È°å»Õ¤Î¸ÀÍÕ¡£¥·¥ç¥Ã¥¯¤Ç¤·¤¿¡£¼ª´·¤ì¤Ê¤«¤ÊÍɤì¤Ê¤¤¿´¹â¹»ÌîµåTK¤Á¤ã¤ó¡¢¤æ¤Ã¤¯¤ê²á¤´¤·¤Æ¤ë¤«¤¤¡£
µîǯ¤â¤³¤³¤Ë½ñ¤¤¤¿¤¬¡¢TKÊì¹»¤ÎÌîµåÉô¥Þ¥Ë¥¢¤È¤·¤Æ¡¢º£Ç¯¤â¤·¤Ã¤«¤ê°ì²óÀ狼¤é±þ±ç¤Ë¹Ô¤Ã¤Æ¤¤¿¤è¡¡²÷¾¡¤â²÷¾¡¡ªTK¤â¸«¤Æ¤¿¤«¡©
¤ÃȬÃúÍɤì¤Ê¤¤¿´¤ª´ê¤¤>Íɤì¤Ê¤¤¿´ËÜʸ¤ò¥¢¥Ã¥×¤·¤Æ¤¯¤À¤µ¤Ã¤¿Êý
¤³¤ÎĹ߷²¿Ë¿¤È¤¤¤¦¥³¥á¥ó¥È¤òºï½ü¤Ç¤¤Þ¤»¤ó¤«?¤³¤Î¥Ú¡¼¥¸¤À¤±¤Ï±ø¤·¤¿¤¯¤Ê¤¤¡£µ¹¤·¤¯¤ª´ê¤¤Ãפ·¤Þ¤¹¡£KNÍɤì¤Ê¤¤¿´¤Ï¤¸¤á¤Þ¤·¤ÆTK¤µ¤ó¡¢¤ß¤Ê¤µ¤ó¡¢¤Ï¤¸¤á¤Þ¤·¤Æ¡£
½é¤á¤Æ¥³¥á¥ó¥È¤µ¤»¤Æ¤¤¤¿¤À¤¤Þ¤¹¡£
TK¤µ¤ó¤Î̾Á°¤Ï»þ¡¹Ë¬Ì䤷¤Æ¤¤¤¿ÊÌ¤Î¥Ö¥í¥°¤ÇÇÒ¸«¤·¤Æ¤¤¤Þ¤·¤¿¡£
¤·¤Ð¤é¤¯¤½¤Î¥Ö¥í¥°¤Ø¹Ô¤¯¤ÎloonyÍɤì¤Ê¤¤¿´¥á¥Ã¥»¡¼¥¸¡¢ºÇ¶á¤Þ¤Çµ¤ÉÕ¤«¤Ê¤«¤Ã¤¿¡£ËÜÅö¤Ë¤´¤á¤ó¤Í¡£
¤³¤ì¡¢¸«¤Æ¤ë¤«¤Ê¡©
»ä¤Ï¡¢£Ô£Ë¤µ¤ó¤¬¤È¤Ã¤¯¤Ëµ¤ÉÕ¤¤¤Æ¤¿¸ÀÍդˡ¢£Ô£Ë¤µ¤ó¤¬¤¤¤Ê¤¯¤Ê¤Ã¤¿º£º¢¡¢¤è¤¦¤ä¤¯µ¤ÉÕ¤¦¤ß¤Í¤³